AZD0156: Potent Selective ATM Kinase Inhibitor for Cancer Research

Executive Summary: AZD0156 is a small-molecule inhibitor that targets the ataxia telangiectasia mutated (ATM) kinase with sub-nanomolar potency and exceptional selectivity (>1000-fold vs. other PIKK kinases) (APExBIO). ATM kinase is critical for DNA double-strand break detection and repair, checkpoint activation, and genomic stability regulation (Kostaras et al. 2020). AZD0156 enhances antitumor efficacy in preclinical models when combined with DNA-damaging agents. The compound is orally bioavailable, with robust quality control and stability protocols. It is supplied by APExBIO for research focused on DNA damage response inhibition and cancer therapy development (product page).

Biological Rationale

ATM kinase is a serine/threonine protein kinase within the phosphatidylinositol 3-kinase-related kinase (PIKK) family. It is activated by DNA double-strand breaks (DSBs) and orchestrates the cellular DNA damage response (DDR) (Kostaras et al. 2020). The ATM pathway regulates cell cycle checkpoints, DNA repair, and apoptosis. Dysfunctional ATM signaling leads to genomic instability, predisposing cells to tumorigenesis. Pharmacological inhibition of ATM is a promising strategy to potentiate the effects of DNA-damaging therapies in cancer research (related guide—this article extends the protocol focus by providing quantitative selectivity data and stability parameters).

Mechanism of Action of AZD0156

AZD0156 (CAS: 1821428-35-6) is a highly specific oral inhibitor of ATM kinase. It binds to the ATP-binding site of ATM, preventing phosphorylation of downstream substrates such as p53, CHK2, and H2AX in response to DSBs (Kostaras et al. 2020). This blockade abrogates cell cycle checkpoint activation and impairs efficient DNA repair, sensitizing cells to genotoxic stress. AZD0156 demonstrates over 1000-fold selectivity for ATM versus other PIKK family members, including ATR and DNA-PKcs, at cellular and biochemical levels (APExBIO).

Evidence & Benchmarks

• AZD0156 inhibits cellular ATM kinase activity with sub-nanomolar IC50 values (IC50 < 1 nM in cell-based assays) (APExBIO).
• Displays >1000-fold selectivity over related kinases ATR, DNA-PKcs, and mTOR in in vitro kinase selectivity panels (APExBIO).
• Enhances antitumor efficacy in preclinical cancer models when combined with DNA double-strand break-inducing agents such as ionizing radiation or topoisomerase inhibitors (Kostaras et al. 2020).
• AZD0156 is orally bioavailable in animal models and achieves consistent plasma exposure at efficacious doses (data on file, APExBIO).
• Currently undergoing early-phase clinical evaluation for safety and preliminary efficacy in advanced cancer patients (Kostaras et al. 2020).

Applications, Limits & Misconceptions

AZD0156 is used to dissect DNA damage response, checkpoint control, and genomic stability mechanisms in cancer research (previous guide—this content updates with detailed selectivity and storage guidance). It is valuable for studies on synthetic lethality, radiosensitization, and combination therapy development. AZD0156 is not recommended for use in non-dividing or DNA repair-proficient normal cells, where ATM inhibition may not yield informative results.

Common Pitfalls or Misconceptions

• AZD0156 is not effective as a single agent in all tumor types; efficacy is context-dependent on DNA repair status and combination partners.
• It does not inhibit ATR or DNA-PKcs at concentrations used for ATM inhibition; off-target effects are minimal at recommended doses.
• Long-term storage of solutions is discouraged; activity may decline if stored in solution at room temperature for extended periods.
• AZD0156 is insoluble in water; DMSO or ethanol are required for stock solutions, with DMSO preferred for higher concentrations.
• Genomic instability from ATM inhibition can have differential effects in non-cancerous versus cancerous cells.

For more on the biochemical context and metabolic adaptation roles, see this article (which AZD0156-focused review extends by adding current clinical trial status and benchmark metrics).

Workflow Integration & Parameters

• Solubility: ≥23.1 mg/mL in DMSO (gentle warming), ≥5.49 mg/mL in ethanol, insoluble in water (APExBIO).
• Stability: Store powder at -20°C; solutions should be used promptly. Avoid long-term storage in solution.
• Purity: >98% (HPLC and NMR, batch QC certificates supplied).
• Recommended Controls: Include a DNA-damaging agent control to assess ATM inhibition sensitization effects.
• Shipping: Blue Ice shipment recommended for small molecule stability.

For actionable protocols and troubleshooting strategies, refer to this protocol overview; this article supplements by specifying storage, purity, and clinical context.

Conclusion & Outlook

AZD0156 represents a benchmark selective ATM kinase inhibitor for DNA damage response and cancer therapy research. Its high selectivity, robust quality control, and defined workflow parameters support reproducible research outcomes. As clinical trials advance, AZD0156 will clarify the therapeutic window for ATM inhibition in oncology. APExBIO continues to supply validated research-grade AZD0156 for laboratory use (product page).